Patients need the patent system to spur the investment necessary for the continued development of life-saving diagnostics and therapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Diamond v. Chakrabarty, 447 U.S. 303 (1980).
Pub L. 96–517, December 12, 1980, codified in 35 U.S.C. §§ 200–12 and implemented by 37 C.F.R. § 401.
Personal communication with executives of a prominent pharmaceutical company, c. 1985.
Parke-Davis & Company v. H.K. Mulford Co., 196 F. 496 (2d Cir. 1912).
Merck & Co. v. Olin Mathieson Chem. Corp., 253 F.2d 156 (4th Cir. 1958).
In re Bergstrom, 427 F.2d 1394 (CCPA 1970).
In re Kratz, 592 F.2d 1169 (CCPA 1979).
Mayo Collaborative Services v. Prometheus Labs., Inc. 566 U.S. 66 (2012).
Association for Molecular Pathology v. Myriad Genetics Inc., 569 U.S. 576 (2013).
Funk Bros. Seed v. Kalo Inoculant, 333 U.S. 127 (1948).
Cuno Engineering Corp. v. Automatic Devices Corp., 314 U.S. 84 (1941).
35 U.S.C. §103.
P.L. 82-593, 35 U.S.C.–Patents Senate report no. 82-1979, 27 June 1952, and House report no. 82-1923, 12 May 1952, comments re Section 103.
Hershey, A. D. & Chase, M. J. Gen. Physiol. 36, 39–56 (1952).
Berk, A. J. & Sharp, P. A. Cell 12, 721–732 (1977).
Maston, G. A., Evans, S. K. & Green, M. R. Annu. Rev. Genomics Hum. Genet. 7, 29–59 (2006).
Coffin, J. M. & Fan, H. Annu. Rev. Virol. 3, 29–51 (2016).
Association of University Technology Managers (AUTM). AUTM’s comments on USPTO’s Patent Eligibility Jurisprudence Study (Docket No. PTO-P-2021-0032) (14 October 2021); https://autm.net/AUTM/media/About-Tech-Transfer/Documents/AUTMs-Comments-on-USPTOs-Patent-Eligibility-Jurisprudence-Study-Docket-Number-PTO-P-2021–0032.pdf
Taylor, D. O. Cardozo Law Rev. 41, 2019–2116 (2020).
Madigan, K. & Mossoff, A. Geo. Mason Law Rev. 24, 939–960 (2017).
German Center for Disease Research (DZIF). Researchers develop first diagnostic test for novel coronavirus in China [press release] (16 January 2020); https://www.dzif.de/en/researchers-develop-first-diagnostic-test-novel-coronavirus-china
US Patent Office (USPTO). 2014 Interim Eligibility Guidance Examples; https://www.uspto.gov/sites/default/files/documents/101_examples_1to36.pdf (2014).
USPTO. 2019 Revised Patent Subject Matter Eligibility Guidance; https://www.uspto.gov/sites/default/files/documents/101_examples_37to42_20190107.pdf (2019)
USPTO. Appendix 1 to the October 2019 Update: Subject Matter Eligibility Life Sciences & Data Processing Examples; https://www.uspto.gov/sites/default/files/documents/peg_oct_2019_app1.pdf (2019)
Acknowledgements
This material was presented at the NAS/CSTL panel Patent Protections for Genetic Products and Processes after AMP v. Myriad (22–23 March 2022). The opinions expressed herein are those of the author alone and do not necessarily represent the views of the author’s current or former employers. The author was a member of the legal team representing Myriad Genetics in AMP v. Myriad.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Coruzzi, L.A. Patents benefit patients and patent reform would spur diagnostic and therapeutic development. Nat Biotechnol 40, 1178–1180 (2022). https://doi.org/10.1038/s41587-022-01405-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01405-z